While developing the hematoma expansion prediction score, associations between hematoma expansion and blend sign, any intrahematoma hypodensity, and time from onset to noncontrast computed tomography <2.5 hours were found.
Investigators performed a pre-planned secondary analysis of the open-label, randomized Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 study, specifically on the magnetic resonance images obtained during the intensive blood pressure lowering portion of the trial.
The investigators of this study did not compare pre- or post-hemorrhage data, precluding their ability to determine the applicability of the findings for improving clinical practice.
Investigators conducted a meta-analysis of trials that reported functional outcomes and mortality rates among patients with intracerebral hemorrhage following intensive blood pressure lowering.
Further research may be necessary to better understand the pathophysiologic mechanisms involved in perihemorrhagic edema evolution and ICH.
For patients with CKD and atrial fibrillation, anticoagulants are linked with an increased risk of ischemic stroke.
Outcomes in intracerebral hemorrhage are less severe in patients with prior NOAC use.
Results from a secondary analysis of the ENCHANTED trial add to a pile of weak data that likely will not affect clinical practice.
Surprisingly, no evidence was found to suggest that patients with these markers benefit from intensive blood pressure reduction.
Intensive antiplatelet therapy appears to reduce risk of recurrence immediately after stroke, but may pose risks further out.
Resumption of oral anticoagulants after intracerebral hemorrhage was found to improve outcomes at 1 year.
The investigators reported no difference in 3-month mortality rates across all 5 studies included in the meta-analysis.
Restarting anticoagulation after both nonlobar and lobar ICH was associated with decreased mortality.
As more patients survive ICH, emphasis is slowly shifting from survival to improving ICH-related morbidity and optimization of functional recovery.
Optimal antiplatelet treatment has yet to be determined for stroke survivors with prior intracerebral hemorrhage.
Among ICH survivors, 63% developed both depression and dementia during a 5-year follow-up study.
Recent research found benefits in outcome outweighed any increase in hemorrhagic complications in patients with large infarcts.
Notably, the location of ICH influenced the association with hematoma volume and growth in patients with prior antiplatelet use.
Cerebral microbleeds increase the risk for symptomatic ICH after thrombolysis for acute ischemic stroke.
Lower serum calcium levels correlate with risk of hematoma expansion in intracerebral hemorrhage.
Risk factors differ for early vs late-onset dementia after ICH.
A joint medical and surgical approach may ensure the best outcome.
Neurology Advisor Articles
- Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults
- Epilepsy's Mobility Problem: Advocating for Changes in Transportation Laws, Public Resources
- The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies
- Women With Epilepsy More Likely to Have Major Depressive Disorder
- Some Common Allergies Linked to Odds of Autism in Children
- CAPPRI Scale is Feasible for Assessing Health-Related Quality of Life in Diabetic Distal Sensorimotor Polyneuropathy
- Long-Term Type 1 Diabetes Associated With Cognitive Decline
- White Matter Hyperintensities in RCVS Vary Over Time
- Disrupted Thalamo-Striato-Hypothalamic Function May Serve as a Good Biomarker for Parkinson Disease
- Levetiracetam Effective as Episodic Migraine Prophylactic